等待開盤 11-11 09:30:00 美东时间
+0.070
+0.76%
今日重点评级关注:摩根士丹利:维持Riot Platforms"超配"评级,目标价从35.5美元升至41美元;Canaccord Genuity:维持塞德斯医疗"买入"评级,目标价从60美元升至68美元
11-10 18:30
Robust NDA submission supported by data from two highly statistically significant Phase 3 trials and a Phase 2b study that each met its primary endpoint and involved a total of more than 1,000 participants living with highly chronic TRD Deep commercial capabilities in place to enable successful laun...
11-09 19:33
今日重点评级关注:康托·菲茨杰拉德:维持Supernus"超配"评级,目标价从67美元升至87美元;丰业银行:维持Atlas Energy Solutions"跑赢大市"评级,目标价从17美元升至18美元
11-05 14:06
今日重点评级关注:Rosenblatt:维持SiTime"买入"评级,目标价从750美元升至900美元;花旗:维持Madrigal Pharmaceuticals"买入"评级,目标价从725美元升至760美元
11-04 18:17
BTIG analyst Thomas Shrader reiterates Compass Pathways (NASDAQ:CMPS) with a Buy and maintains $25 price target.
11-03 23:18
Compass Pathways (NASDAQ:CMPS) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.43) by 27.91 percent. This is a 18.42 percent increase over losses of $(0.38) per share from the same period last year.
11-03 19:32
摩根士丹利在近日发布的研报中首次覆盖八家生物科技公司,业务涉及罕见病、眼科、肺部疾病以及神经精神疾病领域。
10-20 09:40
Congress taking place in New Orleans, LA, from September 14-19. The Company will debut Change the Tune in TRD, a new educational campaign for U.S. HCPs focused on TRD, and present new HEOR data examining the burden of TRD alongside encore presentations from its COMP360 psilocybin clinical developmen...
09-08 18:36
Compass Pathways Plc (($CMPS)) has held its Q2 earnings call. Read on for the m...
08-21 08:21
今日重点评级关注:康托·菲茨杰拉德:维持EyePoint"超配"评级,目标价从47美元升至55美元;伯恩斯坦:维持Figure Technology"跑赢大市"评级,目标价从67美元升至70美元
08-07 13:41